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SLC22A3 polymorphisms do not 
modify pancreatic cancer risk, 
but may influence overall patient 
survival
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Martin Oliverius5, Zdenek Kala6, Daniele Campa7,8, Cosmeri Rizzato7,9, Federico Canzian7, 
Raffaele Pezzilli10, Renata Talar-Wojnarowska11, Ewa Malecka-Panas11, Cosimo Sperti12, 
Carlo Federico Zambon13, Sergio Pedrazzoli14, Paola Fogar15, Anna Caterina Milanetto12, 
Gabriele Capurso16, Gianfranco Delle Fave16, Roberto Valente16, Maria Gazouli17, 
Giuseppe Malleo18, Rita Teresa Lawlor19, Oliver Strobel20, Thilo Hackert20, Nathalia Giese20, 
Pavel Vodicka21,22, Ludmila Vodickova21,22, Stefano Landi8, Francesca Tavano23, 
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Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of 
pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with 
pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging 
the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were 
successfully evaluated in the discovery phase while six significant or suggestive variants entered the 
validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery 
phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic 
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cancer risk. Moreover, rs7758229 associated with the presence of distant metastases, while rs512077 
and rs2504956 correlated with overall survival of patients. Although replicated, the association for 
rs9364554 did not pass multiple testing corrections in the validation phase. Contrary to the discovery 
stage, rs2504938 associated with survival in the validation cohort, which was more pronounced in stage 
IV patients. In conclusion, common variation in the SLC22A3 gene is unlikely to significantly contribute 
to pancreatic cancer risk. The rs2504938 SNP in SLC22A3 significantly associates with an unfavorable 
prognosis of pancreatic cancer patients. Further investigation of this SNP effect on the molecular and 
clinical phenotype is warranted.
Pancreatic ductal adenocarcinoma (PDAC, OMIM: 260350) has an extremely poor prognosis1 mostly due to the 
late diagnosis of disease, when all treatment options are limited. Thus, it is imperative to improve prevention and 
early detection efforts, such as locating genetic markers of PDAC risk that could inform early detection of the 
disease.
There are several established epidemiological risk factors for PDAC, e.g., smoking, obesity, personal history of 
chronic pancreatitis or diabetes, and family history of cancers2. A small fraction of PDACs are caused by high-risk 
predisposing mutations in DNA repair and damage sensing genes, e.g., BRCA1, BRCA2, PALB2, ATM, CDKN2A, 
APC, MLH1, MSH2, MSH6, PMS2, PRSS1, and STK113. Several genome-wide association studies (GWAS) have 
identified several low-penetrance loci associating with PDAC risk4–7. These authors estimated that the current loci 
identified in European populations account for approximately only 5% of the inherited pancreatic cancer risk, 
indicating that a large portion of familial risk alleles remain to be revealed.
The role of the SLC22A subfamily of solute carrier (SLC) transporters in PDAC progression is, at present, not 
well understood. SLC22A1, SLC22A2, and SLC22A3 mediate the transport of a variety of structurally diverse 
cations comprising both endogenous and exogenous compounds, e.g., neurotransmitters such as catecholamines 
and xenobiotics (including drugs), respectively8,9.
Our recent study revealed a highly significant upregulation of SLC22A3 transcripts in PDAC tumors com-
pared with non-neoplastic tissues10. Moreover, a high level of SLC22A3 mRNA in tumors strongly predicted a 
longer overall survival (P = 0.004) in chemotherapy-treated patients. Association studies also suggest that genetic 
variability in SLC22A3 is likely to be associated with the risk of different cancer types. A colorectal cancer GWAS 
reported that rs7758229 in the SLC22A3 gene (Gene ID: 6581) was significantly associated with distal colon can-
cer risk in Asians11. Interestingly, SNP rs9364554 in intron 5 of SLC22A3 was previously shown to associate with 
prostate cancer in Caucasian populations12 suggesting a pleiotropic effect of the SNP.
This study tested the hypothesis that genetic variation in the SLC22A3 gene contributes to pancreatic cancer 
risk and disease survival. The tagging approach of the whole SLC22A3 gene region, including regulatory elements, 
was used in a two-stage genetic association study of Europeans.
Results and Discussion
Associations of SLC22A3 SNPs with pancreatic cancer risk. In this study, an association analysis of 
SNPs tagging the SLC22A3 gene with PDAC risk was performed in a two-stage design comprising in total 1,254 
cases and 3,391 controls of European descent (Table 1).
We genotyped 208 PDAC cases and 381 controls from the Czech Republic in the discovery phase13,14. Three 
SNPs (rs2504938, rs9364554, and rs2457571) were significantly associated with PDAC risk in at least one of the 
genetic models tested (Table 2). These three SNPs were further analyzed in the validation phase comprising 1,046 
and 3,010 controls from the PANDoRA (PANcreatic Disease ReseArch), European case-control study of PDAC15. 
A significant association for rs9364554 (OR = 1.19, 95% CI = 1.02–1.40, p = 0.030) was observed (Table 3), which 
did not pass the FDR test (q = 0.008) for correction of multiple comparisons. Moreover, combined analysis of both 
sets rendered all associations as non-significant (Supplementary Table S1). Thus, the results suggest that genetic 
variability in SLC22A3 probably does not significantly contribute to PDAC risk in the European population.
The trends observed by univariate analyses in the discovery stage did not change in the multivari-
ate analyses adjusted to age, sex, body mass index (BMI), smoking status, and alcohol consumption with 
the exception of rs4708867 where carriage of the rare G allele was associated with an increased PDAC risk 
(Supplementary Table S2). Due to the lack of lifestyle data in the validation phase this association could not be 
replicated.
The present study attempted, for the first time, to find a link between the genetic variability in the SLC22A3 
gene and PDAC risk. The recently reported GWAS on PDAC risk did not find any association with SLC22A3 
tagging variants at genome wide significance6,7. Thus, despite previous reports on association of rs7758229 SNP 
with colorectal cancer risk11 and rs9364554 with prostate cancer risk12,16 the present study confirms that com-
mon genetic variability in SLC22A3 most probably does not modify PDAC risk. Cancer-specific effects, largely 
unknown gene-environmental interactions, and inter-population (even between Europeans) heterogeneity may 
underlie the observed differences.
Associations of SLC22A3 SNPs with pancreatic cancer survival. The second goal of this study was to 
assess whether genetic variability in SLC22A3 associates with major clinical characteristics of PDAC considering 
our previously reported association of intratumoral SLC22A3 gene expression with overall survival of PDAC 
patients10. In the discovery phase, the number of carriers of the T allele or heterozygous genotype in rs7758229 
was significantly higher in patients with metastatic disease than in those without distant metastases (OR = 3.63, 
95% CI = 1.46–9.06, p = 0.006 for heterozygotes compared with the GG genotype carriers and OR = 2.76, 95% 
CI = 1.20–6.32, p = 0.016 for T allele carriers compared with the GG genotype carriers, Table 4). Development of 
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Czech sample set
Controls Cases
p-value†N % N %
Age (mean ± S.D.)* 51.4 ± 14.5 62.8 ± 10.2  < 0.001
Sex* 0.860
 Males 229 60.7 128 61.5
 Females 148 39.3 80 38.5
Body mass index 0.001
(mean ± S.D.)* 30.0 ± 4.2 25.4 ± 4.9
 Missing data 89 62
Smoking status 0.257
 Neversmokers 130 45.0 56 38.9
 Smokers including
  former smokers 159 55.0 88 61.1
 Missing data 88 — 64 —
Alcohol consumption 0.466
 Teetotallers 118 40.5 53 39.2
 Drinkers including 
  former drinkers 173 59.5 92 60.8
 Missing data 86 — 63 —
Clinical stage
 Stage I NA 7 7.4
 Stage IIA NA 12 12.8
 Stage IIB NA 15 16.0
 Stage III NA 13 13.8
 Stage IV NA 47 50.0
 Missing data NA 114 —
Vital status
 Dead NA 172 95.5
 Alive NA 8 4.5
 Missing data NA 28 —
Pandora sample set
Age (mean ± S.D.)# 60.5 ± 12.2 64.1 ± 11.1  < 0.001
Sex# 0.334
 Males 1702 56.6 590 56.6
 Females 1303 43.4 453 43.4
Country and region
 Germany 1032 34.3 94 9.0
  Heidelberg 0 94 —
  Mannheim 1032 0 —
 Italy 1651 53.2 862 80.7
  Bologna 0 70 —
  Carrara 0 209 —
  Florence 435 0 —
  Padua 608 188 —
  Pisa 0 74 —
  Roma 89 109 —
  San Giovanni Rotondo 519 106 —
  Verona 0 106 —
 Poland, Lodz 167 5.5 56 5.3
 Czech Republic, Prague 160 7.0 34 5.0
Clinical stage
 Stage I NA 26 4.5
 Stage IIA NA 64 11.0
 Stage IIB NA 207 35.7
 Stage III NA 104 17.9
 Stage IV NA 179 30.9
 Missing data NA 466 —
Vital status
Continued
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metastases is a major sign of cancer spread due to aggressive behavior of the tumor and predicts poor prognosis. 
Therefore, this SNP was added to the list of SNPs for validation.
Additionally, patients carrying the AA genotype in rs512077 or T allele in rs2504956 had significantly better 
overall survival than the other patients (Fig. 1), suggesting that these SNPs might serve as markers of PDAC 
patient prognosis. None of the other analyzed SNPs in the discovery set were significantly associated with disease 
outcomes.
None of these associations with either metastasis or survival were replicated in the validation phase (all 
p-values > 0.05). However, patients carrying the TT genotype in rs2504938 had highly significantly worse overall 
survival than patients with the CC genotype in the validation set (p = 0.002, Fig. 2) which notably retains sig-
nificance after FDR correction for multiple testing in the validation phase (q = 0.008). However, the combined 
analysis of discovery and validation sets was not significant (p = 0.073, Supplementary Figure S1). Stage-adjusted 
analysis of all three SNPs (rs512077, rs2504956, and rs2504938) in both sets separately and combined also showed 
no significant associations (Supplementary Table S3). When analyzing patients stratified by stage, we observed 
that patients with stage IV disease carrying the TT genotype in rs2504938 had significantly worse OS than CC 
genotype carriers (p = 0.012, Fig. 3). In patients with less advanced disease (stages I–III) no such association was 
found (Fig. 3).
LD analysis in cases from validation phase suggested that rs2504956 and rs512077 are in high LD (r2 = 0.95), 
rs2504938 and rs2504956 in strong LD (r2 = 0.81) and rs2504938 and rs512077 in weak LD (r2 = 0.42). This 
analysis strengthens the observed genetic link of SLC22A3 polymorphisms (rs2504956 in the discovery set and 
rs2504938 in the validation set) with the OS of PDAC patients. A more refined study of these two loci and sur-
rounding sequences may shed more light into the prognostic importance of SLC22A3 variability in PDAC.
A potential functional effect of the rs2504938 and rs2504956 SNPs was tested by two ways. First, we ana-
lyzed the in silico prediction by HaploReg v3 indicating that rs2504938 may alter motifs for DNA binding pro-
teins and transcription factors Hmx_1 (H6 Family Homeobox 1 DNA binding protein, OMIM: 142992) and 
NF-kappaB_known3 (Nuclear Factor Kappa B, OMIM: 164011). Additionally, rs2504956 may alter motifs E2A_2 
and E2A_5 (Transcription Factor 3, OMIM: 147141), Hic1_1 (Hypermethylated in Cancer 1, OMIM: 603825), 
and ZBTB7A_known1 (Zinc Finger- and BTB Domain-containing Protein 7 A, OMIM: 605878). Second, we 
analyzed whether rs2504938 allele distribution correlates with gene expression of SLC22A3 in tumor (n = 17) 
and paired adjacent non-malignant tissues (n = 15) of the subgroup of patients assessed by our previous study10. 
Although there were modest tissue sample numbers available, the comparison suggests no significant correlation 
of rs2504938 or rs2504956 with SLC22A3 expression in PDAC tissues (p > 0.05). Thus, any potential influence 
of the rs2504938 SNP on PDAC survival would not appear to act via the gene expression level. Alternatively, a 
currently unknown link with other, potentially functional, genetic variation may explain the observed association 
with survival of PDAC patients.
Moreover, in the light of recent findings demonstrating that neurotransmitters help stimulate prostate tumor 
growth and metastasis17 and accelerate pancreatic cancer cell growth and invasion18, it would be worthwhile 
examining whether SLC22A3 might be involved in cancer tumorigenesis through the clearance of these active 
compounds.
As our previous study showed an association of SLC22A3 gene expression with overall survival only in patients 
treated with nucleoside analogs10, it would be very interesting to perform a survival analysis stratified by therapy. 
However, PANDoRA does not yet have sufficiently relevant data for such an analysis at present. Together with 
this, variations in age in both sets and BMI distribution in the discovery set are limitations of this study. Although, 
there were no considerable differences between crude and adjusted analyses of both sets, we cannot exclude a 
potential for some false negative findings. Future meta-analysis of results of this and subsequent independent 
studies will help to further evaluate these reported associations.
In conclusion, the present study suggests that common genetic variability in the SLC22A3 gene is not sig-
nificantly associated with risk of PDAC. The rs2504938 SNP was associated with overall survival in the large 
PANDoRA study when evaluated in univariate manner and especially in stage IV patients, although the biological 
basis of this correlation remains to be elucidated.
Subjects and Methods
Study populations. We used a two-step strategy with a discovery phase consisting of biological samples 
from 245 PDAC patients (cases) and 442 controls of Czech Caucasian origin collected in the Czech Republic 
between 2004 and 2010. Patients were eligible for the study, when they fulfilled at least one of the following 
Czech sample set
Controls Cases
p-value†N % N %
 Dead NA 611 25.5
 Alive NA 209 74.5
 Missing data NA 226 —
Table 1.  The baseline characteristics of studied groups of individuals with complete genotypes. In total, 208 
cases and 381 controls in the discovery phase and 1,046 cases and 3,010 controls in the validation phase were 
analyzed after quality control evaluation. *Information about four controls is missing. #Information about five 
controls and three cases is missing. †Significance of differences between cases and controls was evaluated by the 
Mann-Whitney test (sex, smoking status, and alcohol consumption) and by the Fisher’s Exact test (age and body 
mass index). NA = not applicable.
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SNP Controls Cases
OR 95% CI pgenotype N % N %
rs316174 (A> G)
 AA 121 31.9 64 31.2 reference
 AG 182 48.0 107 52.2 1.11 0.76–1.64 0.591
 GG 76 20.1 34 16.6 0.85 0.51–1.41 0.516
 G allele 258 — 141 — 1.03 0.71–1.49 0.861
 A allele* 303 — 171 — 0.79 0.51–1.23 0.307
rs2504956 (C> T)
 CC 240 63.2 115 55.8 reference
 CT 122 32.1 81 39.3 1.39 0.97–2.00 0.074
 TT 18 4.7 10 4.9 1.16 0.52–2.56 0.719
 T allele 140 — 91 — 1.35 0.96–1.92 0.083
 C allele* 362 — 196 — 1.03 0.47–2.27 0.949
rs572149 (A> G)
 AA 153 41.6 149 42.0 reference
 AG 173 47.0 54 51.2 1.08 0.75–1.54 0.675
 GG 42 11.4 5 6.8 0.59 0.31–1.15 0.121
 G allele 214 — 59 — 0.98 0.69–1.39 0.930
 A allele* 326 — 203 — 0.57 0.30–1.08 0.080
rs3120137 (G> A)
 GG 289 75.9 160 77.3 reference
 GA 87 22.8 42 20.3 0.87 0.57–1.32 0.519
 AA 5 1.3 5 2.4 1.82 0.52–6.25 0.356
 A allele 92 — 47 — 0.93 0.62–1.32 0.694
 G allele* 376 — 202 — 1.85 0.53–6.67 0.330
rs512077 (A> G)
 AA 255 67.5 149 72.0 reference
 AG 113 29.9 53 25.6 0.80 0.55–1.18 0.262
 GG 10 2.6 5 2.4 0.85 0.29–2.56 0.780
 G allele 123 — 58 — 0.81 0.56–1.18 0.258
 A allele* 368 — 202 — 0.91 0.31–2.70 0.866
rs675162 (A> G)
 AA 270 73.2 163 79.9 reference
 AG 88 23.8 40 19.6 0.75 0.50–1.15 0.187
 GG 11 3.0 1 0.5 0.15 0.02–1.18 0.071
 G allele 99 — 41 — 0.86 0.45–1.04 0.073
 A allele* 358 — 203 — 0.16 0.02–1.25 0.081
rs394487 (C> T)
 CC 178 47.1 101 48.6 reference
 CT 170 45.0 96 46.2 0.99 0.70–1.41 0.979
 TT 30 7.9 11 5.3 0.65 0.31–1.35 0.243
 T allele 200 — 107 — 0.94 0.67–1.32 0.734
 C allele* 348 — 197 — 0.65 0.32–1.32 0.232
rs10455871(A> T)
 AA 369 97.6 199 96.1 reference
 AT 9 2.4 8 3.9 1.64 0.63–4.35 0.312
 TT 0 0 0 0 NA NA NA
 T allele 9 — 8 — 1.64 0.63–4.35 0.312
 A allele* 378 — 207 — NA NA NA
rs884742 (C> A)
 CC 287 76.3 172 82.7 reference
 CA 82 21.8 35 16.8 0.71 0.46–1.10 0.129
 AA 7 1.9 1 0.5 0.24 0.03–1.96 0.182
 A allele 89 — 36 — 0.70 0.44–1.04 0.074
 C allele* 369 — 207 — 0.25 0.03–2.08 0.202
rs420038 (C> T)
 CC 173 47.0 99 48.8 reference
Continued
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SNP Controls Cases
OR 95% CI pgenotype N % N %
 CT 165 44.8 91 44.8 0.96 0.68–1.37 0.839
 TT 30 8.2 13 6.4 0.76 0.38–1.52 0.434
 C allele 195 — 104 — 0.93 0.66–1.32 0.687
 T allele* 338 — 190 — 0.77 0.39–1.52 0.450
rs1567441 (T> C)
 TT 201 53.2 113 54.6 reference
 TC 159 42.1 83 40.1 0.93 0.65–1.32 0.679
 CC 18 4.8 11 5.3 1.09 0.50–2.38 0.835
 C allele 177 — 94 — 0.94 0.67–1.33 0.743
 T allele* 360 — 196 — 1.12 0.52–2.44 0.769
rs2504938 (C> T)
 CC 234 61.4 110 53.4 reference
 CT 127 33.3 88 42.7 1.47 1.03–2.08 0.032
 TT 20 5.2 8 3.9 0.85 0.36–2.00 0.710
 T allele 147 — 96 — 1.39 0.99–1.96 0.060
 C allele* 361 — 198 — 0.73 0.32–1.69 0.460
rs7745775 (T> G)
 TT 214 56.3 131 63.3 reference
 TG 145 38.2 69 33.3 0.78 0.54–1.11 0.170
 GG 21 5.5 7 3.4 0.54 0.23–1.32 0.177
 G allele 166 — 76 — 0.75 0.53–1.06 0.102
 T allele* 359 — 200 — 0.60 0.25–1.43 0.249
rs9364554 (C> T)
 CC 223 58.8 116 56.0 reference
 CT 144 38.0 77 37.2 1.03 0.72–1.47 0.879
 TT 12 3.2 14 6.8 2.22 1.01–5.00 0.049
 T allele 156 — 91 — 1.12 0.79–1.59 0.512
 C allele* 367 — 193 — 2.22 1.01–5.00 0.048
rs2457571 (T> C)
 TT 103 27.5 46 22.2 reference
 TC 209 55.9 111 53.6 1.19 0.78–1.82 0.415
 CC 62 16.6 50 24.2 1.82 1.09–3.03 0.023
 C allele 271 — 161 — 1.33 0.89–2.00 0.160
 T allele* 312 — 157 — 1.61 1.55–2.44 0.027
rs7758229 (G> T)
 GG 184 48.7 104 50.5 reference
 GT 163 43.1 83 40.3 0.90 0.63–1.28 0.567
 TT 31 8.2 19 9.2 1.09 0.58–2.00 0.798
 T allele 194 — 102 — 0.93 0.66–1.30 0.676
 G allele* 347 — 187 — 1.14 0.63–2.08 0.673
rs12527649 (G> A)
 GG 336 88.7 191 91.8 reference
 GA 41 10.8 16 7.7 0.68 0.37–1.25 0.223
 AA 2 0.5 1 0.5 0.88 0.08–10.00 0.917
 A allele 43 — 17 — 0.69 0.39–1.25 0.227
 G allele* 377 — 207 — 0.91 0.08–10.00 0.939
rs4708867 (A> G)
 AA 307 81.6 164 78.8 reference
 AG 63 16.8 41 19.7 1.22 0.79–1.89 0.375
 GG 6 1.6 3 1.4 0.93 0.23–3.85 0.926
 G allele 69 — 44 — 1.19 0.78–1.82 0.412
 A allele* 370 — 205 — 0.90 0.22–3.70 0.885
rs17593921 (C> T)
 CC 353 93.4 198 95.7 reference
 CT 25 6.6 9 4.3 0.64 0.29–1.41 0.266
 TT 0 0 0 0 NA NA NA
Continued
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criteria: (a) patient had histology- or cytology-confirmed pancreatic adenocarcinoma or (b) at least three of clin-
ical signs of pancreatic cancer (ERCP, EUS with FNAB, mass on CT or MRI, weight loss, anorexia/cachexia, 
obstructive jaundice). Clinical and pathological data on the cases (date of diagnosis, stage, grade, and histologic 
diagnosis where available) were collected from their medical records. The controls were included into the study 
under the condition that the difference in their age was not larger than 5 years from cases recruited in the same 
period. Basic epidemiological data on all participants (personal history, smoking and drinking history, physical 
activity, occupational and nutritional information) were collected (for case and control recruitment criteria see 
refs 13,14). The validation phase consisted of 1,273 cases and 3,466 controls enrolled into the PANcreatic Disease 
ReseArch (PANDoRA) consortium from three other European countries (Germany, Italy, and Poland). For all 
cases and controls a DNA sample from blood and/or pancreatic tissue was available, as well as a minimal set of 
covariates (such as age at diagnosis, sex, disease stage, age of death or at last follow-up for majority of cases). 
Different region-specific subpopulations of unmatched controls have been selected among the general popula-
tion, blood donors and among hospitalized subjects with different diagnosis excluding cancer (described in detail 
in ref. 15).
There are no relevant data concerning chemotherapy treatments and responses so far. Relevant baseline char-
acteristics of the studied populations are shown in Table 1.
Informed consent was obtained from all participating subjects for these studies in accord with the Declaration 
of Helsinki. All samples were coded to protect patient anonymity. The study was approved by the Ethical 
Committee of the University of Heidelberg (reference number S-565/2015). All methods were performed in 
accordance with guidelines and regulations set by the above Ethical Committee.
Selection of polymorphisms. The SLC22A3 gene region together with 10 kb sequences flanking the 5′ and 
3′ ends (chr6: chr6:160680000… 160806000, NCBI assembly 36) was analyzed by HaploView v4.2 program using 
a pairwise tagging approach with r2 > 0.819. SNPs with minor allele frequency (MAF) > 0.01 in HapMap CEU 
sample (International HapMap Project, version 28; http://www.hapmap.org) and at least 75% genotype data were 
identified. Together 24 SNPs tagging 139 alleles in the analyzed region were selected for analysis in the discovery 
phase.
The chromosomal locations and minor allele frequencies of the tested SNP variants are listed in 
Supplementary Table S4.
Genotyping. DNA from the cases and controls in the discovery sample set was isolated from peripheral 
lymphocytes using a BioSprint 15 DNA Blood kit (Qiagen, Valencia, CA) by KingFisher mL automated sys-
tem (Thermo Electron Corporation, Vantaa, Finland) according to the manufacturer’s protocol. DNA from 
participants in the PANDoRA cohort was isolated from whole blood using the Qiagen-mini kit or the AllPrep 
SNP Controls Cases
OR 95% CI pgenotype N % N %
 T allele 25 — 9 — 0.64 0.29–1.41 0.266
 C allele* 378 — 207 — NA NA NA
rs1397168 (A> T)
 AA 263 69.2 142 68.3 reference
 AT 109 28.7 62 29.8 1.05 0.72–1.54 0.784
 TT 8 2.1 4 1.9 0.93 0.27–3.13 0.902
 T allele 117 — 66 — 1.04 0.72–1.52 0.814
 A allele* 372 — 204 — 0.91 0.27–3.03 0.881
rs3088441 (C> T)
 CC 321 84.5 179 86.5 reference
 CT 58 15.3 28 13.5 0.86 0.53–1.41 0.561
 TT 1 0.3 0 0 NA NA NA
 T allele 1 — 0 — 0.85 0.52–1.39 0.515
 C allele* 322 — 179 — NA NA NA
rs2504926 (C> T)
 CC 107 28.4 63 30.6 reference
 CT 198 52.5 110 53.4 0.94 0.64–1.39 0.770
 TT 72 19.1 33 16.0 0.78 0.47–1.30 0.342
 T allele 270 — 143 — 0.90 0.62–1.30 0.576
 C allele* 305 — 173 — 0.81 0.52–1.27 0.356
Table 2.  Results of crude analyses of associations of SLC22A3 SNPs with pancreatic cancer risk in the 
discovery phase. *Rare type genotype as reference. N = numbers of individuals, OR = odds ratio, 95% CI = 95% 
confidence interval. Missing genotypes are due to due to inadequate quantity or quality of DNA. Rs12212246 
SNP was not analyzed due to technical reasons and rs3004079 due to its deviation from Hardy-Weinberg 
equilibrium as described in Patients and Methods. Significant results and SNPs assessed in the validation phase 
are in bold.
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SNP Controls Cases Crude analyses
p
Adjusted analyses*
pgenotype N# % N# % OR 95% CI aOR 95% CI
rs2504956 (C> T)
 CC 1817 61.7 632 61.4 reference reference
 CT 986 33.5 350 34.0 0.98 0.84–1.14 0.793 1.07 0.94–1.27 0.395
 TT 141 4.8 48 4.7 1.02 0.73–1.43 0.901 1.17 0.81–1.69 0.398
 T allele 1127 — 398 — 0.98 0.85–1.14 0.838 1.09 0.93–1.27 0.305
 C allele† 2803 — 982 — 0.97 0.69–1.35 0.867 1.16 0.81–1.66 0.427
rs512077 (A> G)
 AA 2101 70.5 726 70.1 reference reference
 AG 809 27.2 280 27.0 0.99 0.85–1.18 0.984 0.95 0.80–1.13 0.596
 GG 69 2.3 30 2.9 0.79 0.51–1.23 0.303 1.07 0.66–1.72 0.784
 G allele 878 — 310 — 0.98 0.84–1.14 0.785 0.96 0.82–1.14 0.660
 A allele† 2910 — 1006 — 1.26 0.81–1.92 0.301 1.08 0.67–1.74 0.755
rs2504938 (C> T)
 CC 1733 59.0 631 60.6 reference reference
 CT 1055 35.9 358 34.4 1.07 0.92–1.25 0.359 1.01 0.86–1.19 0.929
 TT 149 5.1 52 5.0 1.04 0.75–1.45 0.800 1.15 0.81–1.62 0.437
 T allele 1204 — 410 — 1.07 0.93–1.23 0.364 1.02 0.88–1.20 0.771
 C allele† 2788 — 989 — 0.98 0.71–1.35 0.921 1.15 0.77–1.52 0.433
rs9364554 (C> T)
 CC 1792 62.5 597 60.2 reference reference
 CT 912 31.8 340 34.3 0.89 0.77–1.04 0.156 1.20 1.01–1.42 0.034‡
 TT 162 5.7 55 5.5 0.98 0.71–1.35 0.908 1.15 0.81–1.65 0.429
 T allele 1074 — 395 — 0.91 0.78–1.05 0.190 1.19 1.02–1.40 0.030‡
 C allele† 2704 — 937 — 0.98 0.71–1.33 0.899 1.08 0.77–1.52 0.647
rs2457571 (T> C)
 TT 885 30.8 327 32.1 reference reference
  TC 1431 49.8 485 47.5 1.09 0.93–1.28 0.300 1.04 0.87–1.24 0.645
 CC 559 19.4 208 20.4 0.99 0.81–1.20 0.946 1.21 0.97–1.51 0.097
 C allele 1990 — 693 — 1.06 0.91–1.23 0.449 1.09 0.93–1.29 0.296
 T allele† 2316 — 812 — 1.06 0.89–1.27 0.513 1.18 0.97–1.44 0.093
rs7758229 (G> T)
 GG 1637 55.3 568 54.7 reference reference
 GT 1121 37.8 403 38.8 0.96 0.83–1.12 0.640 1.13 0.96–1.33 0.138
 TT 204 6.9 68 6.5 1.04 0.78–1.41 0.787 1.00 0.73–1.39 0.981
 T allele 1325 — 471 — 0.98 0.85–1.14 0.738 1.11 0.95–1.30 0.174
 G allele† 2962 — 971 — 0.95 0.71–1.27 0.706 0.97 0.71–1.32 0.826
Table 3.  Results of validation study of putative loci in SLC22A3 associating with pancreatic cancer risk in 
the discovery phase. *Adjusted to age, sex, and country of origin. #N = number of individuals. †Rare genotype as 
reference. ‡Result did not pass the FDR test for multiple comparisons (q = 0.008). Significant results are in bold.
SNP M0 M1
OR 95% CI pgenotype N % N %
rs7758229
 GG 33 66.0 19 41.3 reference
 GT 11 22.0 23 50.0 3.63 1.46–9.06 0.006
 TT 6 12.0 4 8.7 1.16 0.29–4.63 0.836
 T alelle 17 — 27 — 2.76 1.20–6.32 0.016
 G allele* 44 — 42 — 0.70 0.18–2.65 0.598
Table 4.  Analyses of distribution of SLC22A3 SNPs in pancreatic cancer patients stratified by the presence 
of distant metastases in the discovery phase. *TT genotype as reference. N = numbers of individuals, 
OR = odds ratio, 95% CI = 95% confidence interval. Missing genotypes are due to due to inadequate quantity 
or quality of DNA or due to missing data. All SNPs were analyzed but to retain concise style only significant 
associations are reported. Significant results are in bold.
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Isolation kit (both Qiagen) using provider’s protocol. DNA was quantified by Quant-iT PicoGreen DNA Assay 
Kit (Invitrogen).
In the discovery phase, 24 SNPs were analyzed in DNA from 245 PDAC cases and 442 controls of Czech origin 
using KASPar technology (LGC Genomics, Hoddesdon, UK). Validation failed for rs12212246 due to unspecific 
amplification and therefore this SNP was not further analyzed.
During the validation phase, six candidate SNPs (i.e., those that showed an association in the discovery phase 
with either the risk or clinical outcomes of PDAC in the Czech cohort) were genotyped in the PANDoRA sam-
ple set consisting of 1,273 cases and 3,466 controls of European origin. Genotyping was performed at National 
Institute of Public Health, Prague, Czech Republic by allelic discrimination using TaqMan technology (Life 
Figure 1. Associations of SLC22A3 rs512077 and rs2504956 SNPs with overall survival of PDAC patients 
in the discovery phase Kaplan–Meier survival curves for patients with wild type (solid line) vs. patients 
with rare allele (dashed line) are displayed. The difference in the mean survival between the compared groups 
of patients was significant (p = 0.034 and p = 0.045 for rs512077 and rs2504956 SNPs, respectively). Hazard 
ratios, 95% confidence intervals, and p-values calculated by the stage-adjusted Cox regression are presented in 
Supplementary Table S3.
Figure 2. Associations of SLC22A3 rs2504938 SNP with overall survival of PDAC patients in both phases 
Kaplan–Meier survival curves for patients with CC genotype (solid line) vs. patients with TT genotype 
(dashed line) are displayed. The difference in the mean survival between the compared groups of patients was 
significant (p = 0.002) in the validation phase. Hazard ratios, 95% confidence intervals, and p-values calculated 
by the stage-adjusted Cox regression are presented in Supplementary Table S3.
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Technologies Corp., Foster City, CA) in a ViiA7 real-time instrument with a 384-well block (Life Technologies). 
SNP assay reaction conditions are summarized in Supplementary Table S5.
Quality control was performed by determination of duplicate samples for approximately 10% of the samples 
in both phases. The genotyping concordance between duplicate samples exceeded 99%. All samples with less than 
75% successful genotypes for all SNPs were discarded from further analysis. In total, the generated genotypes for 
208 cases and 381 controls in the discovery phase and 1,046 cases and 3,010 controls in the validation phase were 
then analyzed. Together 23 SNPs were successfully genotyped.
Statistical analysis. Hardy Weinberg Equilibrium (HWE) was first examined in control subjects for each 
SNP. Genotype distribution of the studied SNPs did not deviate from HWE (p > 0.05) with the exception of 
rs3004079. The rs3004079 variant was therefore excluded from further analyses. Unconditional logistic regres-
sion was then used to assess the association of the 22 remaining SNPs with PDAC risk in the discovery phase. 
Co-dominant, dominant, and recessive genetic models were evaluated. Crude and adjusted for age (continuous), 
sex, and country of origin odds ratios (OR), 95% confidence intervals (CI), and p-values were calculated for each 
SNP. Age-, sex-, body mass index-, smoking status-, and alcohol consumption-adjusted analyses were performed 
by logistic regression in the discovery phase.
Associations of SNPs with prognostic clinical data (tumor size, presence of lymph node and distant metas-
tases) were evaluated by the Cochran’s and Mantel-Hanszel statistics. Overall survival (OS) was defined as time 
elapsed from diagnosis to patient death, or to the last date at which the patient was known to be alive. Patients 
lost to follow up were excluded from analyses. Survival functions were plotted by the Kaplan-Meier method and 
statistical significance was evaluated by the Log-rank test. Stage-adjusted hazard ratios were then calculated by 
Cox regression. A p-value of less than 0.05 was considered statistically significant. Analyses were conducted by 
the statistical program SPSS v15.0 (SPSS, Chicago, IL).
The six SNPs genotyped in the validation phase were evaluated using the same statistical methods as for the 
discovery phase.
In multiple testing adjustments, as Bonferroni’s correction was considered too stringent because of linkage 
disequilibrium (LD) among the SNPs we tested, the Benjamini-Hochberg false discovery rate (FDR) test20 was 
used for the evaluation of results in the validation phase.
The functional relevance of the SNP showing significant association (rs2504938) was analyzed in silico by 
HaploReg v2 and v321. Information about the observed association of this SNP with clinical phenotype of PDAC 
was submitted to NCBI (The National Center for Biotechnology Information) ClinVar database (http://www.ncbi.
nlm.nih.gov/clinvar).
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